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The acid hydrolysis of natural vitamin B12 yields a series of products in which the acetamide 
or propionamide side chains on the corrin framework are converted to the corresponding 
acids. These acids can be derivatised with further functionalities. We have separated in 
particular the b- and the d-acid derivatives 1 and 2 (see scheme 1) since functionalisation at 
these positions of the corrin ring keeps affinity for B12 transport proteins in general intact. 
Although evident from 1H NMR investigations, the authenticity of 1 and 2 has not been 
supported by X-ray structure analyses so far. Coupling of ethyl N-(3-aminopropyl)-N-
(pyridin-2-ylmethyl)glycinate 3 to the carboxylate groups in 1 and 2 via peptide synthetic 
methods gave the vitamin B12 derivatives 4 and 5. The structures of 4 and 5 could be 
characterized by an X-ray analysis, thereby unambiguously confirming the presence of the b- 
and d-acid in 1 and 2 respectively. Reaction of 4 and 5 in water with the complexes 
[Re(OH2)3(CO)3]+ and [99mTc(OH2)3(CO)3]+ 7 gave the corresponding B12 derivatives 
[Re(4)(CO)3] 8, [Re(5)(CO)3] 9 and their 99mTc homologues 10 and 11.  
 
Introduction 
Cyanocobalamin or vitamin B12 (abbreviated B12 in the following parts) is, like most of the 
vitamins, not synthesized by mammals but by a few bacteria only. This contrasts the fact that 
essentially all higher organisms are B12 dependent and especially humans have developed a 
highly complex system for uptake and biochemical conversion of B12 to the two coenzymes 
methyl- and adenosyl-cobalamin. Excellent and comprehensive reviews appeared recently 
covering all aspects of vitamin B12 chemistry, biochemistry and physiology.[1-3] Due to the 
mandatory requirement of B12 in humans, it has been proposed to use it as a Trojan horse for 
cyto- or radiotoxic compounds. Vitamin mediated drug uptake by rapidly growing and 
dividing aggressive tumours expressing a high density of transcobalamin receptors seems to 
be an attractive strategy.[4] Inspecting the B12 molecule, covalent conjugation of such 
bioactive molecules can be performed at several native functionalities. According to structure 
activity relationships, the 5’-OH group of the α-ribofuranoside in the backloop would be a 
versatile site, however, due to the complexity of site specific derivatization, not much 
functionalisation has been done.[5] Furthermore the b- and the d-acid are attractive sites for 
conjugation of functionalities or metal complexes. It could be shown by Hogenkamp et al. 
that covalent binding of a spacer with DTPA and subsequent labelling with 111In lead to good 
tumour but also to high kidney uptake.[6,7] We have chosen b- and d-acids for derivatization 
since it is known that the affinity of such derivatives for transcobalamin proteins decreases 
indeed but is still strong enough for binding and transportation.[8-10] In our own previous 
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work, we introduced histidine derivatives through the b- and d-acid into B12.[11,12] Preliminary 
studies with the 99mTc labelled B12 derivatives showed very promising behaviour in vitro and 
in vivo. Biologically active molecules have also been introduced by direct coordination to the 
Co(III) in B12 or through the cyano group bound to it. Grissom et al. coupled fluorescing 
molecules via a Co-C bond to B12 and used this derivative for lymphatic mapping.[13,14] We 
bound several rhenium, technetium and platinum complexes to the cyano group and could 
confirm the authenticity by X-ray structure analysis.[15,16] 
The preferred site for derivatization is the periphery of the corrin ring, which is, besides the 
backloop, bound to three propionamide and two acetamide groups. Scheme 1 gives an 
overview of the structure of B12 and the relative positions of the respective groups. 
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Scheme 1. Assignment of the side chains on the periphery of the corrin in B12. 
 
Characterisation of B12 derivatives is mainly performed with NMR spectroscopy. NMR 
restrained molecular mechanics/molecular dynamics methods have successfully been used to 
structurally characterise B12 derivatives.[17] Still, X-ray structure analysis would be preferable, 
but B12 derivatives are sometimes very difficult to crystallise.  Milestones in B12 structure 
analyses were certainly the elucidation of native B12 by Hodgkin et al.,[18] the structure of 
methyl-cobalamin and finally adenosyl-cobalamin (coenzyme B12).[19,20] X-ray 
crystallography of B12 and its derivatives has recently been reviewed extensively.[21-23] 
Inspecting these structures reveals the surprising fact that no X-ray analysis of a B12 
derivative is available, in which one of the amide side chains has been functionalised. To our 
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knowledge, the only X-ray structure with derivatization at the corrin ring is available at all is 
one in which the C10-H has been replaced by a chloride.[24] We therefore present in this study 
the synthesis and the first X-ray structures of B12 derivatized at either the b- or the d-acid with 
a ligand for binding to transition metals. These vitamin B12 derivatives are labelled in a 
second step with the fac-[M(CO)3]+ (M = Re, 99mTc) moiety. 
 
Results and Discussion 
Syntheses: Mild acid hydrolysis of the amide side chains in B12 yields a mixture of 
monocarboxylic b- and d- and e-acids. These can be separated and received in pure form by 
sequential ion-exchange chromatography and RP-HPLC methods.[8,25-27] With a slightly 
modified method (see experimental section) we received 280 mg (15%) of the b-acid 1 and 
132 mg (7%) of the d-acid 2 respectively starting with 1.9 g of vitamin B12 (scheme 2). These 
yields are consistent with the literature, however, we isolated only 94 mg (5%) of the e-acid. 
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Scheme 2. Mild hydrolysis yields the b- and d-acid of B12 yields b- and d-acids 1 and 2 after 
separation.[8,25-27] 
           
The assignment of the exact structures of the hydrolytic products turned out to be difficult. 
The main product, compound 1 in this study, was first thought of be the e-acid due to its 
ability to hydrolyse the back-loop and due to results of X-ray and neutron diffraction 
studies.[26,28] Subsequent neutron diffraction studies assigned it as the b-acid, an assumption 
that was later confirmed by sophisticated multi-dimensional NMR measurements.[29-32] The 
problem with X-ray analyses was due to the similar diffraction power of the OH and NH2 
groups. Cobalamin crystals were rarely received in a quality as required for an unambiguous 
differentiation between these two groups. An X-ray structure analysis of respective 
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derivatives such as esters or alkyl-amides would solve this problem (see later). However, any 
attempts failed by now since the conjugated groups prevented crystallization or were 
disordered.[23,33] 
Since we are interested in the introduction of coordinating ligands rather than simple organic 
groups, we selected the tridentate chelate N-(pyridin-2-ylmethyl)glycine. This basic ligand 
structure is known to form strong and in vivo stable complexes with the fac-[M(CO)3]+ 
moiety.[34] To enable conjugation of the basic ligand framework to a biomolecule, an alkyl 
chain with a terminal functionality is introduced to the secondary amine adapting known 
synthetic pathways.[35] In particular, the 3-aminopropyl chain bound to the secondary amine 
group in the basic ligand structure gives compound 3 which comprises now the tridentate 
chelate (after de-esterification) and an additional primary amine for coupling with the b- and 
d-carboxylic acid respectively (Scheme 3).  
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Scheme 3. Derivatisation of B12 d-acid 2 with ligand 3 to yield compound 5. 
 
Reaction of 1 and 2 in the presence of ligand 3 and coupling reagents gave the corresponding 
derivatives 4 (b-acid) and 5 (d-acid) after HPLC purification in about 30% yield. In order to 
obtain the free tridentate ligand, the ester functionality can be removed from the ligand by 
alkaline hydrolysis. It turned out however, that the hydrolysis in advance is not required since 
coordination to the fac-[M(CO)3]+ moiety catalysed this reaction and lead to immediate 
hydrolysis during the coordination process.  
X-ray quality crystals could be grown by very slow vapour diffusion of either acetone or 
acetonitrile into an aqueous solution of 4 or 5 respectively. The crystal of 4 yielded a structure 
of exceptional quality for B12 crystals, which is shown by the R1 value of 5.9% for the strong 
reflections. Furthermore, for the whole dataset till a resolution of 0.75 Å, there were more 
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than 92% observed reflections that were having at an intensity higher than 2 sigma. On the 
other hand, the crystals of 5 were not diffracting enough on our Mo home source, therefore 
we collected synchrotron data till 0.99 Å resolution on the F1 beamline at HASYLAB/DESY. 
Both structures crystallized in the “typical” B12 space group P212121. In the literature the 
family of B12 crystal structures with the P212121 space group was subdivided in 4 clusters 
based on the ratio of the cell axes b/a and c/a.[21] Introduction of the rather large unit of 3 into 
the B12 framework apparently did not interrupt the normal B12 crystal packing. The 
corresponding ratios of the crystal structures of 4 and 5 are 1.40 and 1.39 for b/a and 1.61 and 
1.61 for c/a respectively. These values are clearly indicating that both 4 and 5 belong to the 
cluster II. Furthermore an overlay of both structures reveals the stunning almost identical 
conformation of all substituted as well as unsubstituted amide side chains (Fig. 1). The Ortep 
plots of 4 and 5 are shown in Figures 2 and 3. It should be noted that both structures represent 
the ethyl ester of the pendent ligand since the coupling was performed directly with 
compound 3. This is confirmed by the mass spectra of both compounds (see experimental 
part). Due to disorder in the structure of 5, we were only able to localize the terminal CH3 
group in 4 but not in 5, hence, it does not appear in the line drawings or the ORTEPs. 
 
Figure 1. Overlay of the X-ray structures of 4 and 5. 
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Figure 2. Ortep plot of 4. Hydrogen atoms and some water molecules were omitted for clarity. 
 
 
Figure 3. Ortep plot of 5. Hydrogen atoms and some water molecules were omitted for clarity.  
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The nitrogen of the pyridine in 4 is hydrogen bonded to a five membered cluster of water 
molecules that makes extensive contacts between three B12 molecules. The nitrogen atom of 
the pyridine in 5 makes two hydrogen bonded contacts with symmetry generated 
neighbouring molecules via a Y shaped alignment of three water molecules.  
 
Table 1. Crystal and Structure Refinement Data for 4 and 5. 
Compound No. 4 5 
   
X-ray source sealed Mo tube F1 beamline at 
HASYLAB/ DESY 
Detector Stoe IPDS MarCCD 165 
Wavelength / Å 0.71073  0.7500 
Formulaa C79H132CoN16O27P C77H122CoN17O24P 
Mr 1827.91 1759.82 
Crystal system orthorhombic orthorhombic 
Space group  P212121 P212121 
a/Å 15.9566(6) 15.9200(15) 
b/Å 22.3021(8) 22.1900(18) 
c/Å 25.6917(12) 25.680(3) 
V/Å3 9142.8(6) 9071.8(15) 
Z 4 4 
Dc/g cm-3 1.328 1.288 
Goodness-of-fit on F2 1.046 1.138 
Rb,c 0.0594 0.0824 
wR2b,d 0.1600 0.1979 
Flack parameter 0.009(9) -0.06(3) 
Max., min. peaks/e·Å-3 1.034 and -0.815 0.698 and -0.852 
 
a
 Formulas are different since various amounts of solvent molecules were found in the 
structures.  b Observation criterion: I > 2σ(I). c R = Σ||Fo| - |Fc||/Σ||Fo|. d wR2 = {Σ[w(Fo2 - 
Fc2)2]/Σ[w(Fo2)2]}1/2 
 
 
Complexation with [Re(OH2)3(CO)3]+ and labelling with [99mTc(OH2)3(CO)3]+: In both 
compounds 4 and 5 the carboxylate group is still protected by an ester functionality. Mild 
alkaline hydrolysis of the ethyl ester over extended time period would convert the ester to the 
acid and renders all three coordination sites available but decomposition products were 
observed during this process, presumably due to c-lactam formation. The formation of the c-
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lactam of B12 in alkaline media is a known reaction.[36,37] During the reaction of 4 and 5 with 
[Re(OH2)3(CO)3]+ in water, we found that ester cleavage was catalysed by the presence of the 
metal complex, probably after coordination to one or two of the nitrogen donors. A similar 
observation was made with histidine complexes in which an ester function was also converted 
quantitatively to the carboxylate during coordination.[12] After the reaction, we found a 
mixture of two complexes, one of which was the desired product 8 (for the b-derivative). The 
highest yield with clear product formation was received via an indirect pathway. Formation of 
the complex [Re(3)(CO)3] 6 from 3 and [Re(OH2)3(CO)3]+ is quantitative. Complex 6 can 
now be coupled to 1 to receive directly 8 in very good yield and without byproducts (scheme 
4). The second strategy described before refers to prelabelling approach in the labelling of 
biomolecules with 99mTc. Since yields are usually far from quantitative, prelabelling is not the 
method of choice. We observed previously, the ester bonds are much more efficiently cleaved 
in the presence of technetium than in the presence of rhenium. This observation was 
confirmed by reacting [99mTc(OH2)3(CO)3]+ 7 with 4 or 5 at moderate temperature. We 
observed exclusively the formation of the desired products 10 and 11 without having evidence 
for the byproducts as observed in the corresponding reactions with [Re(OH2)3(CO)3]+. 
Comparison of the retention times of 10 and 11 with 8 and 9 confirms the identity of the 
corresponding homologues. These complexes are stable in human serum albumin for at least 
24h without loss of technetium complexes or reoxidation to [99mTcO4]-. Compounds 10 and 11 
represent therefore excellent radiotracers for uptake studies in cancer cells or microbial 
infections. 
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Scheme 4. Reaction pathways to 8, i) direct reaction of 4 with [Re(OH2)(CO)3]+ to 8 
(postlabelling) or ii) conjugation of preformed [Re(3)(CO)3] 6 to 1 (prelabelling). 
 
Conclusions 
We have synthesised two B12 derivatives that comprise tridentate chelators attached to the 
corrin periphery. For the first time, an X-ray structure analysis of a B12 compound with corrin 
side chain derivatization could be received, confirming the assignments of earlier NMR 
investigations. The derivatives coordinate to [Re(OH2)3(CO)3]+ and to [99mTc(OH2)3(CO)3]+, 
representing therefore useful radiolabeled B12 compounds for in vitro and in vivo studies. 
  
Experimental Section 
General Remarks: Reagent grade chemicals were from Merck, Dietikon (CH), Aldrich or 
Fluka, Buchs (CH) and were used without further purification. HPLC analyses were 
performed on a Merck-Hitachi L-7000 system equipped with a EG&G Berthold LB 508 
radiometric detector, using Waters XTerra RP8 columns (5 µm particle size, 1 x 100 mm) and 
a flow rate of 1 ml/min. Chromatograms were recorded at 250 and 360 nm. Sodium acetate 
buffer A1 was prepared by mixing 2.9 ml acetic acid and 4.55 ml sodium hydroxide 2 M in 
900 ml water and 100 ml methanol. Tris buffer A2 was prepared by dissolving tris-
(hydroxymethyl)-aminomethane (605 mg) in water, adding HCl 2 M to reach a pH of 8.2, 
adjusting the volume to in 1000 ml, and adding acetonitrile (10 ml). Eluent B was always 
methanol. Preparative HPLC separations were performed on a Varian Prostar system 
equipped with two Prostar 215 pumps and a Prostar 320 UV/Vis detector, using Waters 
XTerra Prep RP8, columns (5 µm particle size, 3 x 100 mm and 30 x 100 mm). Flow rates 
were 4 ml/min for the 3 x 100 mm column and 30 ml/min for the 30 x 100 mm column. 
UV/Vis spectra were recorded on a Varian Cary 50 spectrometer, IR spectra were recorded on 
a Bio-Rad FTS-45 spectrometer in KBr. ESI-MS were recorded on a Merck Hitachi M-8000 
spectrometer. In Re-compounds, the values of the 187Re isotope are reported. NMR spectra 
were recorded on a Bruker DRX 500 MHz spectrometer.  
Cobalamin derivatives were desalted by applying an aqueous solution of the compound to a 
Chromafix RP18ce cartridge, followed by thoroughly rinsing with water. The desalted 
product was then eluated with methanol, the solvent removed and the product dried in high 
vacuum. 
The ethylester of N-(3’-aminopropyl)-N-(pyridin-2-ylmethyl)glycinate 3 was prepared as 
described for its pentyl analogue.[35] Cyclisation of the compound under basic conditions was 
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found. Therefore, the Boc protected precursor was stored and deprotected with TFA just prior 
to further functionalisation. [Re(((3’-amino-propyl)-pyridin-2-ylmethyl-amino)-acetic 
acid)(CO)3] 6 was prepared by reacting fully deprotected ((3’-amino-propyl)-pyridin-2-
ylmethyl-amino)-acetic acid with (NEt4)2[Re(Br)3(CO)3] in water (see below). The syntheses 
of the b- and d-acid 1 and 2 of B12 were performed according to literature but with some slight 
modifications in the purification process as described below.[8] 
 
X-ray crystallography: 
Suitable crystals were covered with Paratone N oil, the mother liquid removed and the 
crystals finally mounted with the help of magnetic loops. Single-crystal diffraction data of 4 
were collected on a Stoe IPDS diffractometer at 183(2) K using graphite-monochromated Mo 
radiation (0.71073 Å). Data were corrected for Lorentz and polarisation effects as well as for 
absorption. Single-crystal diffraction data of 5 were collected at the F1 beamline at 
HASYLAB/DESY on a Huber Kappa diffractometer at 100(2) K, using λ = 0.7500 Å 
radiation and a MarCCD 165 detector. Integration of intensities was performed using the XDS 
program.[38] A series of 190 frames with a 1.0 degree phi rotation and an exposure time of 90 
seconds was collected. The XDS program was compensating for the beam intensity loss 
between two refills. Both structures were solved with direct methods using SIR97[39] and 
refined by full-matrix least-squares methods on F2 with SHELXL-97.[40] Appropriate 
restraints had to be used to constrain the geometry of the highly flexible ligand part in 5. The 
terminal carbon atom of the ethyl ester in 5 could not be localized in the electron density map. 
ORTEP plots were generated by the Ortep32 software and are drawn at 30% probability. The 
crystal data and refinement parameters of 4 and 5 are summarized in Table 1. CCDC-630989 
and CCDC-630990 contain the supplementary crystallographic data for this paper. They can 
be obtained free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
 
Synthesis of Vitamin B12 b- and d-acid 1 and 2: Vitamin B12 (1.88 g, 1.39 mmol) was 
hydrolized in HCl 0.1 M (190 ml) as described in literature.[8] The purification was modified 
in the following way. The Dowex column allowed, after desalting the crude reaction mixture 
by phenol extractions, the isolation of three fractions. The first one contained exclusively 2, a 
second one a mixture of 1 and 2 and finally a third one 2 and the e-acid. The second fraction 
(mixture of 1 and 2) was separated by preparative HPLC (column: Waters XTerra Prep RP8, 
5 µm, 30 x 100 mm; buffer A1; gradient: 0.5% min-1 starting from 100% A). The mixture of 2 
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and e-acid was separated on the same system but using the buffer A2. Compound 1 was 
isolated in a yield of 280.6 mg (14.9%), compound 2 in a yield of 131.5mg (7.0%), and 94.26 
mg (5.0%) of the e-acid. Assignment of the isomers was done by comparison with the HPLC 
retention order given in literature. 
 
Synthesis of B12-b-(3) 4: A solution of freshly prepared 3 (361 µmol) in 1 ml of water was 
given to 1 (65.0 mg, 48.1 µmol). EDC (46.1 mg, 240 µmol) was added and the pH adjusted to 
5.5 with NaOH 0.1M. After stirring at room temperature for 15 hours, HPLC analysis 
exhibited about 50% of product 4. More EDC (46.1 mg, 240 µmol) was added but even 
extended stirring at room temperature did not lead to further significant formation of 4. The 
solvent was removed in vacuo, and the residue purified by preparative HPLC (buffer A1, 
gradient: 0.5% min-1 starting from 100% A1). The main fraction was collected, the solvent 
was removed in vacuo, and the product was desalted to give 4 in a yield of 25.8 mg (16.2 
µmol, 33.3%). Rt = 13.1 min (gradient A1/B). 1H NMR (500MHz, CD3OD, 300K) δ 8.43 (d, 
1H, J=4.9 Hz, L12), 7.77 (t, 1H, J=7.7 Hz, L10), 7.58 (d, 1H, J=7.8 Hz, L9), 7.28 (t, 1H, 
J=6.9 Hz, L11), 7.25 (s, 1H, B7), 7.12 (s, 1H, B2), 6.56 (s, 1H, B4), 6.27 (d, 1H, J=3.0Hz, 
R1), 6.04 (s, 1H, C10). 13C NMR (125.8MHz, CD3OD, 293K) δ: 181.65, 180.20, 177.67, 
176.73, 175.65, 175.58, 175.43, 174.72, 174.48, 174.34, 173.19, 167.22, 166.98, 160.49, 
160.44, 149.67, 143.55, 138.86, 138.34, 135.72, 133.88, 131.56, 125.07, 124.04, 117.92, 
112.65, 108.77, 105.21, 95.76, 88.05, 86.50, 83.74 (d, JC-P=5.6), 76.40, 75.55, 73.69 (d, JC-
P=6.1), 71.66, 70.80, 70.56, 62.74, 61.79, 60.85, 60.45, 57.75, 56.97, 55.91, 55.67, 55.13, 
53.31, 52.64, 50-49 (1C below solvent), 46.91, 43.99, 43.16, 40.22, 38.88, 37.06, 35.43, 
33.58, 33.09, 33.06, 32.42, 29.74, 28.01, 27.96, 27.52, 21.07, 20.61, 20.43, 20.26 (d, JC-
P=3.8), 20.02, 17.67, 17.16, 16.51, 16.21, 14.71. ESI-MS: m/z = 806.5 [M+H+Na]2+, 795.6 
[M+2H]2+. UV/Vis: λ/nm (ε/mol⋅l-1⋅cm-1) = 278.0 (8500), 361.1 (26500), 549.1 (8000). A full 
1H NMR spectra is shown in the supplementary material. The ester can be hydrolyzed to the 
acid. Due to self catalysed cleavage (see above) this compound has to be labelled 
immediately. Labelling can be performed directly with 4 without the need of prior de-
esterification. Rt = 10.8 min. 
 
Synthesis of B12-d-(3) 5: The procedure is similar as for 4. Compound 2 (9.3 mg, 6.9 µmol). 
was reacted with 3 (7 µmol) and EDC (6.6 mg, 34 µmol) as described for the synthesis of 4. 
After HPLC purification, the product 5 was isolated in a yield of 3.6 mg (33%). Rt = 15.5 min 
(gradient A1/B). 1H NMR (500MHz, CD3OD, 300K) δ 8.46 (d, 1H, L12), 7.77 (t, 1H, L10), 
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7.56 (d, 1H, L9), 7.32 (t, 1H, L11), 7.25 (s, 1H, B7), 7.12 (s, 1H, B2), 6.56 (s, 1H, B4), 6.29 
(d, 1H, R1), 6.05 (s, 1H, C10). 13C NMR (125.8MHz, CD3OD, 293K) δ: 181.72, 180.27, 
177.77, 177,64, 177.50, 175.86, 175.69, 175.47, 174.72, 174.36, 173.84, 173.05, 167.25, 
167.05, 160.65, 149.63, 143.58, 138.90, 138.43, 135.60, 134.00, 131.59, 125.10, 124.06, 
118.02, 112.62, 108.82, 105.24, 95.76, 88.11, 86.56, 83.84 (d, JC-P=5.6), 76.49, 75.65, 73.77 
(d, JC-P=6.1), 70.85, 62.84, 61.75, 60.86, 60.51, 57.79, 57.02, 55.73, 55.15, 53.10, 52.62, 
46.95, 44.02, 43.19, 40.25, 38.59, 36.37, 35.45, 33.78, 33.63, 33.13, 32.52, 32.45, 29.79, 
28.21, 27.78, 27.57, 21.09, 20.60, 20.51, 20.33 (d, JC-P=3.8), 20.09, 17.65, 17.24, 16.53, 
16.25, 14.77. 31P NMR (300MHz, CD3OD, 300K) δ 1.373. ESI-MS: m/z = 1612 [M+Na]+, 
1590 [M+H]+, 806 [M+H+Na]2+, 795.1 [M+2H]2+. UV/Vis: λ/nm (ε/mol l-1 cm-1) = 279.0 
(13400), 361.1 (23300), 549.1 (7200). Free acid Rt = 10.6 min (A1/B). Full 1H and 13C NMR 
spectra are shown in the supplementary material. 
 
Synthesis of [Re(3)(CO)3] 6: 75 mg (0.09 mmol) of complex [NEt4]2[ReBr3(CO)3] was 
dissolved in 10 ml of water and a solution of 36 mg fully deprotected 3 (0.13 mmol) in 
methanol was added. The solution was heated to 70 – 80° C for 2 h. The proceeding of the 
reaction can be monitored by HPLC. After this time period, the peak Rt = 6.2 min 
([Re(OH2)3(CO)3]+) completely disappeared and a new peak (product 6) with Rt = 15.1 min 
appeared. After 2 hours the conversion was complete. Upon cooling a white powder 
precipitated from solution. This precipitate was filtered, washed with small amounts of cold 
water and dried in vacuo. Yield 32 mg (72%), the rest remaining in the filtrate. It is important 
to apply temperatures above 70° C in order to ensure ester hydrolysis during complexation. 
1H NMR (300MHz, CD3OD, 300K) δ 8.87 (d, 1H), 8.05 (t, 1H), 7.57 (d, 1H), 7.50 (t, 1H), 
4.67 (2, 1H), 4.48 (s, 1H), 3.90 (t, 2H), 3.28 (d, 1H), 3.54 (t, 1H), 3.40 (t, 2H), 1.93 (m, 2H). 
ESI-MS: m/z = 493.80  [M+H]+. Elemental analysis (%) calcd. for C12H18F3N3O7Re (6⋅TFA): 
C, 25.76; H, 3.24; N, 7.51; found: C, 25.23; H, 3.21; N, 7.33. 
 
Synthesis of [Re(4)(CO)3] 8: Two synthetic procedures are possible. The direct reaction of 4 
with [Re(OH2)3(CO)3]+ in water gives compound 8 in good yield. Alternatively, the complex 
6 can be preformed by the reaction of fully deprotected 3 and [Re(OH2)3(CO)3]+ followed by 
coupling to 1 as described in the following part. Compound 1 (26.7 mg, 19.8 µmol), complex 
6 (29.2 mg, 60 µmol), EDC (11.5 mg, 60 µmol) and N-hydroxy-succinimide (6.9 mg, 60 
µmol) were dissolved in a mixture of water (5 ml) and DMSO (0.5 ml) and the pH was 
adjusted to 5.5. After 5 hours at room temperature, HPLC analysis exhibited about 33% of 
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product 8. More EDC and N-hydroxy-succinimide were added and stirring continued for 3 
days with addition of EDC and N-hydroxy-succinimide in 24 hour intervals. The water was 
removed in vacuo and the product precipitated by adding diethyl ether. The oily suspension 
was centrifugated and decanted. Washing with diethyl ether was repeated twice until a fine 
precipitate formed. The crude product was dried at high vacuum, purified by preparative 
HPLC (A1, gradient 1% min-1 starting from 100% A1) and desalted to give 8 in a yield of 9.1 
mg (23%). Rt = 14.2 min (gradient A1/B). νmax (KBr)/cm-1 2927, 2134, 2024, 1913, 1897, 
1662. 1H NMR (500MHz, CD3OD, 300K) δ 8.1 (d, 1H, J=4.5 Hz, L12), 8.10 (t, 1H, J=8 Hz, 
L10), 7.73 (m, 1H, L9), 7.54 (m, 1H, L11), 7.26 (s, 1H, B7), 7.14 (s, 1H, B2), 6.59 (m, 1H, 
B4), 6.27 (s, 1H, R1), 6.05 (s, 1H, C10). 13C NMR (125.8 MHz, CD3OD, 300K) δ: 198.39, 
198.24, 197.46, 183.33, 181.75, 180.28, 177.72, 177.68, 176.77, 175.74, 175.69, 175.46 (2C), 
174.90, 174.76, 174.36, 167.27 (2C), 160.90, 153.72, 143.63, 141.85, 138.39, 135.77, 133.97, 
131.63, 127.20, 125.19, 117.99, 112.65, 105.25, 102.57, 95.74, 88.13, 86.59, 83.83 (d, JC-
P=4.5), 76.52, 75.74, 73.72 (d, JC-P=5.4), 70.89, 69.44, 68.87, 62.90, 62.04, 60.55, 55.27, 
55.77, 49-50 (1C below solvent), 46.93, 44.35, 43.04, 40.29, 38.01, 36.44, 35.51 (2C), 33.66, 
33.11 (2C), 32.45 (2C), 29.74, 27.60, 26.46, 21.13, 20.64, 20.47, 20.31 (d, JC-P=3.2), 20.09, 
17.65, 17.25, 16.69, 16.24. ESI-MS: m/z = 1831.7 [M+H]+, 916.1 [M+H]2+. UV/Vis: λ/nm = 
278.0, 361.1, 519.9, 551.1. A full 1H NMR spectra is shown in the supplementary material. 
 
Synthesis of [Re(5)(CO)3] 9: Compound 9 was prepared following one of the procedures as 
described for 8. Full 1H and 13C NMR are shown in the supplementary material. 
 
Labelling of 3 and 4 with [99mTc(OH2)3(CO)3]+ (10 and 11): Solutions of the precursor 
[99mTc(OH2)3(CO)3]+ 7 were prepared from [99mTcO4]- as described in literature or using the 
Isolink® kits as commercially available from Mallinckrodt Med. B.V. Petten NL.[41] Labelling 
of 4 and 5 was performed in a 10 ml glass vial with rubber stopper which was flushed with N2 
for 10 min. 20 µl of a solution of the respective B12 derivative (0.001 M in water), 20 µl or 40 
µl MES buffer pH 6.2 (final conc. 0.1 M) and 160 or 1940 µl of a [99mTc(OH2)3(CO)3]+ 
solution was added and the reaction mixture kept at 75°C for 1 - 2 hours. Final B12 
concentration was 10-4 to 10-5 M.  HPLC analyses with γ-detection were performed to verify 
full conversion of the 99mTc precursor. Under these conditions, ester protecting groups in the 
chelators were cleaved to give the tridendate complexation. Comparison with the retention 
times of the corresponding rhenium complexes confirmed the authenticity of the labelled 
compounds. Rt (8) = 15.1 min, Rt (9) = 17.9 min. The delay is due to the separation of the 
 15 
two detectors. Both compounds labelled with 99mTc were stable in human serum albumin for 
at least 24 h at 37° C. 
 
Supporting information: CCDC-630989 and CCDC-630990 contain the supplementary 
crystallographic data for this paper. These data can be obtained free of charge from The 
Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 1H NMR 
spectra for compounds 4, 8, 5 and 9 and 13C NMR spectra for 5 and 9 are available with the 
supporting information.  
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Fig S1: 1H-NMR of B12-b-(3) (4) 
 
 
Fig S2: 1H-NMR of [(4)-Re(CO)3] (8) 
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Fig S3. 13C NMR of compound 5 
 
 
Fig. S4. 1H NMR of compound 5 
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Fig S5. 13C NMR of compound 9 
 
 
 
Fig S6. 1H NMR of compound 9 
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